In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Jaguar Health Inc’s stock clocked out at $0.93, down -6.05% from its previous closing price of $0.99. In other words, the price has decreased by -$6.05 from its previous closing price. On the day, 0.17 million shares were traded. JAGX stock price reached its highest trading level at $1.04 during the session, while it also had its lowest trading level at $0.9182.
Ratios:
To gain a deeper understanding of JAGX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.52 and its Current Ratio is at 0.81. In the meantime, Its Debt-to-Equity ratio is 5.67 whereas as Long-Term Debt/Eq ratio is at 1.52.
Upgrades & Downgrades
. In the most recent recommendation for this company, Cantor Fitzgerald on July 07, 2021, initiated with a Overweight rating and assigned the stock a target price of $5.
On July 11, 2017, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $2.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAGX now has a Market Capitalization of 3888539 and an Enterprise Value of 33068812. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.29 while its Price-to-Book (P/B) ratio in mrq is 1.09. Its current Enterprise Value per Revenue stands at 2.806 whereas that against EBITDA is -1.07.
Stock Price History:
The Beta on a monthly basis for JAGX is -0.42, which has changed by -0.963633 over the last 52 weeks, in comparison to a change of 0.17511821 over the same period for the S&P500. Over the past 52 weeks, JAGX has reached a high of $33.25, while it has fallen to a 52-week low of $0.95. The 50-Day Moving Average of the stock is -36.35%, while the 200-Day Moving Average is calculated to be -71.41%.
Shares Statistics:
It appears that JAGX traded 211.73K shares on average per day over the past three months and 164030 shares per day over the past ten days. A total of 3.69M shares are outstanding, with a floating share count of 2.23M. Insiders hold about 40.41% of the company’s shares, while institutions hold 2.55% stake in the company. Shares short for JAGX as of 1765756800 were 245697 with a Short Ratio of 1.16, compared to 1763078400 on 102632. Therefore, it implies a Short% of Shares Outstanding of 245697 and a Short% of Float of 7.199999999999999.
Earnings Estimates
Its stock is currently analyzed by 1.0 different market analysts. The consensus estimate for the next quarter is -$2.04, with high estimates of -$2.04 and low estimates of -$2.04. Analysts are recommending an EPS of between -$23.81 and -$23.81 for the fiscal current year, implying an average EPS of -$23.81. EPS for the following year is -$5.68, with 1.0 analysts recommending between -$5.68 and -$5.68.
Revenue Estimates
In . The current quarter, 1 analysts expect revenue to total $4.21M. It ranges from a high estimate of $4.21M to a low estimate of $4.21M. As of . The current estimate, Jaguar Health Inc’s year-ago sales were $3.51MFor the next quarter, 1 analysts are estimating revenue of $3.67M. There is a high estimate of $3.67M for the next quarter, whereas the lowest estimate is $3.67M.
A total of 1 analysts have provided revenue estimates for JAGX’s current fiscal year. The highest revenue estimate was $12.56M, while the lowest revenue estimate was $12.56M, resulting in an average revenue estimate of $12.56M. In the same quarter a year ago, actual revenue was $11.69MBased on 2 analysts’ estimates, the company’s revenue will be $26.55M in the next fiscal year. The high estimate is $34.87M and the low estimate is $18.23M.
